Brooks Cassandra C, Jabbehdari Sayena, Gupta Preeya K
Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA.
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Clin Ophthalmol. 2020 Jan 13;14:89-94. doi: 10.2147/OPTH.S238756. eCollection 2020.
Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain.
炎症和疼痛是眼部手术后常见的两种症状。皮质类固醇作为控制术后炎症和疼痛的核心治疗方法被广泛应用。患者对术后眼药水治疗方案的依从性差、局部眼药水的生物利用度有限以及许多此类眼药水所用防腐剂的负面影响,使得新型疗法在治疗术后疼痛和炎症方面具有充分的理由。这篇文献综述将聚焦于泪小管内缓释地塞米松(Dextenza,美国马萨诸塞州贝德福德市的Ocular Therapeutix公司生产)在眼部炎症和疼痛管理中的作用。